Publications by authors named "Joe Stephenson"

Claim this Profile
E
Eosinophilic Myocarditis in Children From Toxocara Canis: A Case and Review of the Literature.
Joe Stephenson, Mario O'Connor, Maria Hoyos, Anthony Merlocco, Jason Johnson

Circ Heart Fail· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EPR25-130: Multi-Year Review of the Management of Patients in a High-Risk Breast Clinic.
Marie Smith, William Kirian, Gina Franco, Joe J Stephenson, LeAnn Perkins

J Natl Compr Canc Netw· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic accuracy and performance of artificial intelligence in measuring left atrial volumes and function on multiphasic CT in patients with atrial fibrillation.
Gilberto J Aquino, Jordan Chamberlin, Basel Yacoub, Madison R Kocher, Ismail Kabakus, Joe Stephenson

Eur Radiol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Tracy Murray Stewart, Daniel Von Hoff, Michael Fitzgerald, Laurence J Marton, Carlos H Roberto Becerra, Joe J Stephenson

Cancer Chemother Pharmacol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.
Aditya Bardia, Mrinal Gounder, Jordi Rodon, Filip Janku, Martijn P Lolkema, Joe J Stephenson

Oncologist· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
Daniel P Petrylak, Philip Kantoff, Nicholas J Vogelzang, Anthony Mega, Mark T Fleming, Joe J Stephenson

Prostate· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors.
Kyriakos P Papadopoulos, Larry Gluck, Lainie P Martin, Anthony J Olszanski, Anthony W Tolcher, Joe Stephenson

Clin Cancer Res· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).
Mark M Awad, Quincy S-C Chu, Leena Gandhi, Joe J Stephenson, Ramaswamy Govindan

Lung Cancer· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Alex A Adjei, Donald A Richards, Anthony El-Khoueiry, Fadi Braiteh, Carlos H R Becerra, Joe J Stephenson

Clin Cancer Res· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.
Mitesh J Borad, Shantan G Reddy, Nathan Bahary, Hope E Uronis, Darren Sigal, Joe Stephenson

J Clin Oncol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer.
Niall Tebbutt, Dusan Kotasek, Howard A Burris, Lee S Schwartzberg, Herbert Hurwitz, Joe Stephenson

Cancer Chemother Pharmacol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Luciano J Costa, Suzanne R Fanning, Joe Stephenson, Lawrence B Afrin, Emily Kistner-Griffin

Leuk Lymphoma· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Robert M Jotte, Daniel D Von Hoff, Fadi Braiteh, Carlos R Becerra, Donald A Richards, Joe Stephenson

Invest New Drugs· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.
Eric Van Cutsem, Cathy Eng, Elzbieta Nowara, Anna Swieboda-Sadlej, Niall C Tebbutt, Joe Stephenson

Clin Cancer Res· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours.
Lot A Devriese, Kevin M Koch, Marja Mergui-Roelvink, Gemma M Matthys, Wen Wee Ma, Joe J Stephenson

Invest New Drugs· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
Joe J Stephenson, John Nemunaitis, Anil A Joy, Julie C Martin, Ying-Ming Jou

Lung Cancer· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients.
Kevin M Koch, Young-Hyuck Im, Sung-Bae Kim, Ander Urruticoechea Ribate, Joe Stephenson

Clin Pharmacol Drug Dev· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors.
Lee S Rosen, Lara Lipton, Timothy J Price, Neil D Belman, Ralph V Boccia, Joe J Stephenson

BMC Cancer· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies.
John F Gerecitano, Joe J Stephenson, Nancy L Lewis, Anna Osmukhina, Jianguo Li

Invest New Drugs· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors.
Elisabeth I Heath, Jeffrey Infante, Lionel D Lewis, Thehang Luu, Joe Stephenson

Cancer Chemother Pharmacol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.
John Nemunaitis, Alain Mita, Joe Stephenson, Monica M Mita, John Sarantopoulos

Cancer Chemother Pharmacol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy.
Ramesh K Ramanathan, Joe J Stephenson, Glen J Weiss, Linda A Pestano, Ann Lowe

Invest New Drugs· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MG98, a second-generation DNMT1 inhibitor, in the treatment of advanced renal cell carcinoma.
Robert J Amato, Joe Stephenson, Sebastien Hotte, John Nemunaitis, Karl Bélanger

Cancer Invest· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer.
Janessa J Laskin, Garth Nicholas, Christopher Lee, Barbara Gitlitz, Mark Vincent, Joe Stephenson

J Thorac Oncol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.
Caroline J Breitbach, James Burke, Derek Jonker, Joe Stephenson, Andrew R Haas

Nature· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis